Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Neo HCC neoadjuvant immunotherapy combinations in resectable hepatocellular carcinoma
2022-502840-11-00Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Neoadjuvant Tecentriq + Avastin, Neoadjuvant Tecentriq + tiragolumab and Neoadjuvant Tecentriq + RO7247669 (3 arms). Primary endpoint: MPR rate. Started Nov 2023; status: completed.
02
Drugs
atezolizumabbevacizumabtiragolumabtobemstomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-502840-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502840-11-00.